DOW JONES27,081.36-879.44 -3.15%
S&P 5003,128.21-97.68 -3.03%
NASDAQ8,965.61-255.67 -2.77%

Mizuho Maintains Buy on Revance Therapeutics, Raises Price Target to $39

Mizuho maintains Revance Therapeutics (NASDAQ:RVNC) with a Buy and raises the price target from $34 to $39.

Benzinga · 01/23/2020 13:13

Mizuho maintains Revance Therapeutics (NASDAQ:RVNC) with a Buy and raises the price target from $34 to $39.